2024全年財務結果：截至2024年12月31日，研發費用爲5,900萬美元，相比2023年同期的3,390萬美元增長了2,510萬美元，主要是由於與癌後藥物相關的Phase 2 STRIDES試驗發展及生產費用增加了2,280萬美元。2024年全年一般和行政費用爲1,920萬美元，較2023年同期的1,450萬美元增加了470萬美元，這主要是由於2024年發放的股票期權補償費用的增加。2024年淨虧損爲7,110萬美元，每個普通股基本和攤薄後的虧損爲$(6.63)，與2023年同期每個普通股基本和攤薄後的虧損爲$(38.17)相比有所減少。截至2024年12月31日，BioAge擁有約3.543億美元的現金和現金等價物。根據目前的運營計劃，預計現有現金和現金等價物足以支持運營和資本支出至2029年。

以上內容來自Benzinga Earnings專欄，原文如下：

Full Year 2024 Financial Results

Research and development expenses were $59.0 million for the year ended December 31, 2024, compared to $33.9 million for the same period in 2023. The $25.1 million increase in research and development expenses was primarily attributable to a $22.8 million increase in costs related to the development of azelaprag driven by the Phase 2 STRIDES trial and costs related to the manufacture of azelaprag.

General and administrative expenses were $19.2 million for the year ended December 31, 2024, compared to $14.5 million for the same period in 2023. The $4.7 million increase was primarily attributable to an increase in stock-based compensation expense associated with option grants issued in 2024 to employees, executives, board members and advisors.

Net loss was $71.1 million for the year ended December 31, 2024, or $6.63 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $63.9 million, or $38.17 per weighted-average common share outstanding, basic and diluted, for the same period in 2023.

As of December 31, 2024, BioAge had approximately $354.3 million in cash and cash equivalents. Based on our current operating plan, BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029.